InterPAD - DETAILS

letrozole, 112809-51-5, Femara, 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile, Letrozol, CGS 20267, Letoval, CGS-20267, Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-, 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile, Femera, 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile, HSDB 7461, UNII-7LKK855W8I, NSC-759652, 7LKK855W8I, CCRIS 8822, CHEBI:6413, DTXSID4023202, CHEMBL1444, 4-[(4-CYANOPHENYL)(1H-1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE, DTXCID503202, Letrozole [USAN:USP:INN:BAN], NSC719345, NSC 759652, 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile, NCGC00016973-01, CAS-112809-51-5, LETROZOLE (MART.), LETROZOLE [MART.], LETROZOLE (USP-RS), LETROZOLE [USP-RS], KISQALI FEMARA CO-PACK COMPONENT LETROZOLE, C17H11N5, LETROZOLE (EP IMPURITY), LETROZOLE [EP IMPURITY], LETROZOLE (EP MONOGRAPH), LETROZOLE [EP MONOGRAPH], LETROZOLE (USP MONOGRAPH), LETROZOLE [USP MONOGRAPH], Letrozole (USAN:USP:INN:BAN), SMR000466343, Femara (TN), LETRAZOLE, SR-01000759382, letrozolum, Letrozole (JAN/USP/INN), 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile, Letrozole?, Letrozole Tablets, 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole, FEM-345, Femara, Letrozole, Letrozole- Bio-X, CGS20267, 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile), LETROZOLE [INN], LETROZOLE [JAN], LETROZOLE [MI], LETROZOLE [HSDB], LETROZOLE [USAN], Prestwick0_001025, Prestwick1_001025, Prestwick2_001025, Prestwick3_001025, Femara (TN) (Novartis), LETROZOLE [WHO-DD], SCHEMBL4331, 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole, BIDD:PXR0130, BSPBio_001209, MLS000759455, MLS001424038, MLS002584991, MLS006010040, BIDD:GT0015, SPBio_003070, BPBio1_001331, GTPL5209, LETROZOLE [ORANGE BOOK], Letrozole, >=98% (HPLC), BDBM13061, EX-A965, L02BG04, HMS1571M11, HMS2051E08, HMS2089L22, HMS2098M11, HMS2233C23, HMS3369E11, HMS3393E08, HMS3651K05, HMS3715M11, Pharmakon1600-01502354, AMY32541, BCP23354, Tox21_110719, Tox21_303572, MFCD00866241, NSC759652, s1235, STL451047, AKOS005145822, AB07525, AC-1193, BCP9000848, CCG-100849, CS-1776, DB01006, KS-1269, NC00099, NSC-719345, NCGC00016973-02, NCGC00016973-03, NCGC00016973-06, NCGC00257460-01, BL164620, HY-14248, BCP0726000213, 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole, 4,2,4-Triazol-1-ylmethylene)dibenzonitrile, AB00514009, L0248, NS00000663, SW197294-4, A25380, C08163, D00964, EN300-264820, AB00514009-05, AB00514009-07, AB00514009-08, AB00514009-09, AB00514009_10, AB00514009_11, Q194974, W-60273, 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile, LETROZOLE COMPONENT OF KISQALI FEMARA CO-PACK, Q-201291, SR-01000759382-4, SR-01000759382-5, 4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile, BRD-K88789588-001-03-2, 4,4 -(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile, F2173-0288, Z1741968261, 4,4'-((1H-1,2,4-Triazol-1-yl)-methylene)dibenzonitrile, Letrozole, European Pharmacopoeia (EP) Reference Standard, Letrozole, United States Pharmacopeia (USP) Reference Standard, 4-[1-(4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE, Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material

Name	Letrozole
PubChem CID	3902
Molecular Weight	285.30g/mol
Synonyms	letrozole, 112809-51-5, Femara, 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile, Letrozol, CGS 20267, Letoval, CGS-20267, Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-, 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile, Femera, 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile, HSDB 7461, UNII-7LKK855W8I, NSC-759652, 7LKK855W8I, CCRIS 8822, CHEBI:6413, DTXSID4023202, CHEMBL1444, 4-[(4-CYANOPHENYL)(1H-1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE, DTXCID503202, Letrozole [USAN:USP:INN:BAN], NSC719345, NSC 759652, 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile, NCGC00016973-01, CAS-112809-51-5, LETROZOLE (MART.), LETROZOLE [MART.], LETROZOLE (USP-RS), LETROZOLE [USP-RS], KISQALI FEMARA CO-PACK COMPONENT LETROZOLE, C17H11N5, LETROZOLE (EP IMPURITY), LETROZOLE [EP IMPURITY], LETROZOLE (EP MONOGRAPH), LETROZOLE [EP MONOGRAPH], LETROZOLE (USP MONOGRAPH), LETROZOLE [USP MONOGRAPH], Letrozole (USAN:USP:INN:BAN), SMR000466343, Femara (TN), LETRAZOLE, SR-01000759382, letrozolum, Letrozole (JAN/USP/INN), 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile, Letrozole?, Letrozole Tablets, 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole, FEM-345, Femara, Letrozole, Letrozole- Bio-X, CGS20267, 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile), LETROZOLE [INN], LETROZOLE [JAN], LETROZOLE [MI], LETROZOLE [HSDB], LETROZOLE [USAN], Prestwick0_001025, Prestwick1_001025, Prestwick2_001025, Prestwick3_001025, Femara (TN) (Novartis), LETROZOLE [WHO-DD], SCHEMBL4331, 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole, BIDD:PXR0130, BSPBio_001209, MLS000759455, MLS001424038, MLS002584991, MLS006010040, BIDD:GT0015, SPBio_003070, BPBio1_001331, GTPL5209, LETROZOLE [ORANGE BOOK], Letrozole, >=98% (HPLC), BDBM13061, EX-A965, L02BG04, HMS1571M11, HMS2051E08, HMS2089L22, HMS2098M11, HMS2233C23, HMS3369E11, HMS3393E08, HMS3651K05, HMS3715M11, Pharmakon1600-01502354, AMY32541, BCP23354, Tox21_110719, Tox21_303572, MFCD00866241, NSC759652, s1235, STL451047, AKOS005145822, AB07525, AC-1193, BCP9000848, CCG-100849, CS-1776, DB01006, KS-1269, NC00099, NSC-719345, NCGC00016973-02, NCGC00016973-03, NCGC00016973-06, NCGC00257460-01, BL164620, HY-14248, BCP0726000213, 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole, 4,2,4-Triazol-1-ylmethylene)dibenzonitrile, AB00514009, L0248, NS00000663, SW197294-4, A25380, C08163, D00964, EN300-264820, AB00514009-05, AB00514009-07, AB00514009-08, AB00514009-09, AB00514009_10, AB00514009_11, Q194974, W-60273, 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile, LETROZOLE COMPONENT OF KISQALI FEMARA CO-PACK, Q-201291, SR-01000759382-4, SR-01000759382-5, 4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile, BRD-K88789588-001-03-2, 4,4 -(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile, F2173-0288, Z1741968261, 4,4'-((1H-1,2,4-Triazol-1-yl)-methylene)dibenzonitrile, Letrozole, European Pharmacopoeia (EP) Reference Standard, Letrozole, United States Pharmacopeia (USP) Reference Standard, 4-[1-(4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE, Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material
Drug Type	Small molecule
Formula	C₁₇H₁₁N₅
SMILES	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
InChI	1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
InChIKey	HPJKCIUCZWXJDR-UHFFFAOYSA-N
CAS Number	112809-51-5
ChEMBL ID	CHEMBL1444
ChEBI ID	CHEBI:6413
TTD ID	D0C1WH
Drug Bank ID	DB01006
KEGG ID	C08163
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Berberine, Letrozole
Partner Name	Berberine
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	Our results suggest that concomitant treatment of LTZ-BBR increases the efficacy of chemotherapeutic agents with low BBR concentrations, especially in chemo-resistant malignancies.